Table 1 Patient characteristics

From: Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation

  Year periods P-value
  19982002 n=240 (%) 20032007 n=326 (%) 20082012 n=354 (%)  
Follow-up time (months)     <0.001
 Median (range) 130 (1–176) 80 (1–122) 29 (1–63)  
Age (years)     0.003
 Median (range) 47 (18–69) 49 (18–68) 49 (18–69)  
 <50 144 (60%) 167 (51%) 182 (51%)  
 50 or older 96 (40%) 159 (49%) 172 (49%)  
Sex     0.798
 Male 149 (62%) 193 (59%) 214 (60%)  
 Female 91 (38%) 133 (41%) 140 (40%)  
Disease     <0.001
 AML 83 (35%) 113 (35%) 144 (41%)  
 ALL 31 (13%) 38 (12%) 50 (14%)  
 MDS 39 (16%) 42 (13%) 24 (7%)  
 CML/MPD 39 (16%) 16 (5%) 3 (1%)  
 ML 36 (15%) 81 (25%) 81 (23%)  
 ATL 7 (3%) 26 (8%) 44 (12%)  
 Others 5 (2%) 10 (3%) 8 (2%)  
Disease risk     <0.001
 Low 47 (19%) 30 (9%) 23 (6%)  
 Intermediate 119 (50%) 158 (48%) 179 (51%)  
 High 74 (31%) 138 (42%) 152 (43%)  
Donor source     <0.001
 Related peripheral blood 143 (59%) 149 (46%) 94 (27%)  
 Related bone marrow 10 (4%) 18 (6%) 13 (4%)  
 Unrelated bone marrow 83 (35%) 133 (41%) 235 (66%)  
 Unrelated cord blood 4 (2%) 26 (8%) 12 (3%)  
Conditioning     <0.001
 Myeloablative 139 (58%) 133 (41%) 190 (53%)  
TBI-based 101 (42%) 59 (18%) 86 (24%)  
Bu-Cy 38 (16%) 74 (23%) 104 (29%)  
 Reduced intensity 101 (42%) 193 (59%) 164 (46%)  
GVHD prophylaxis     <0.001
 Cyclosporine 240 (100%) 216 (66%) 57 (16%)  
Alone 55 (23%) 71 (32%) 9 (16%)  
plus MTX 164 (68%) 144 (67%) 43 (75%)  
plus MMF 2 (1%) 1 (1%) 5 (9%)  
 Tacrolimus 0 (0%) 110 (34%) 297 (84%)  
Alone 0 21 (19%) 24 (8%)  
plus MTX 0 89 (81%) 265 (89%)  
plus MMF 0 0 (0%) 8 (3%)  
 Usage of ATG 37 (15%) 39 (12%) 50 (14%)  
PS     0.021
 0 191 (78%) 278 (85%) 270 (76%)  
 1 38 (16%) 40 (12%) 74 (21%)  
 2 7 (3%) 7 (2%) 9 (3%)  
 3 4 (2%) 1 (1%) 1 (1%)  
HCT-CI     0.517
 0 141 (59%) 197 (60%) 228 (64%)  
 1–2 66 (28%) 86 (26%) 77 (22%)  
3 33 (14%) 43 (13%) 49 (14%)  
  1. Abbreviations: AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; ATG=antithymoglobulin; ATL=adult T-cell leukemia/lymphoma; Bu=busulfan; CY=cyclophosphamide; HCT-CI=hematopoietic cell transplant comorbidity index; MDS=myelodysplastic syndrome; MMF=mycophenolate mofetil; ML=malignant lymphoma; MPD=myeloproliferative disease; MTX=methotrexate; PS=performance status.